Want to see AU:VIT full AI Analyst Report?
VIT Stock Chart & Stats
AU$0.03
>-AU$0.01(-6.67%)
At close: 4:00 PM EDT
AU$0.03
>-AU$0.01(-6.67%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.07
Previous CloseN/A
Volume435.95K
Average Volume (3M)496.33K
Market Cap
AU$12.59M
Enterprise ValueAU$27.00
Total Cash (Recent Filing)AU$5.35M
Total Debt (Recent Filing)AU$16.40M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield10.53%
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding662,741,800
10 Day Avg. Volume828,123
30 Day Avg. Volume496,335
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.38
Price to Sales (P/S)0.13
P/FCF Ratio-76.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulated Medicinal-cannabis FocusA focused position in regulated medicinal cannabis gives the company a defined operating market and a business model tied to an established therapeutic category. Regulatory market participation can support product legitimacy and create a durable platform for serving patients and healthcare-related demand.
Solid Balance-sheet BaseA comparatively solid equity base and manageable leverage provide financial resilience relative to a more highly stressed capital structure. This can preserve flexibility to fund operations, absorb business volatility, and pursue opportunities while reducing dependence on immediate external financing.
Long-term Operating ScaleStrong revenue expansion over the broader cycle and improving scale in earlier periods indicate that the business has demonstrated an ability to grow its operating base. If execution stabilizes, that established scale may support more efficient operations and future earnings recovery.
Bears Say
Profitability DeteriorationThe sharp gross-profit decline and reversal from profit to loss signal meaningful pressure on the economics of the business, not merely slower growth. Persistently weaker profitability would reduce retained cash, limit reinvestment capacity, and make earnings recovery more dependent on operational improvement.
Negative Cash GenerationNegative operating and free cash flow weaken the company’s ability to fund operations and investment internally. The reversal from prior positive generation raises the risk that continued underperformance could require financing or asset decisions, while also making the durability of current cash earnings less certain.
Weaker Capital CushionRising debt alongside falling equity reduces the buffer available to absorb further operating weakness, even though overall leverage remains manageable. Combined with the latest loss, this can constrain capital allocation, increase reliance on recovery in earnings, and weaken financial flexibility over coming quarters.
Cronos Australia Ltd. News
VIT FAQ
What was Cronos Australia Ltd.’s price range in the past 12 months?
Cronos Australia Ltd. lowest share price was AU$0.02 and its highest was AU$0.07 in the past 12 months.
What is Cronos Australia Ltd.’s market cap?
Cronos Australia Ltd.’s market cap is AU$12.59M.
When is Cronos Australia Ltd.’s upcoming earnings report date?
Cronos Australia Ltd.’s upcoming earnings report date is Mar 02, 2027 which is in 162 days.
How were Cronos Australia Ltd.’s earnings last quarter?
Cronos Australia Ltd. released its earnings results on Aug 25, 2026. The company reported -AU$0.005 earnings per share for the quarter.
Is Cronos Australia Ltd. overvalued?
According to Wall Street analysts Cronos Australia Ltd.’s price is currently Overvalued.
Does Cronos Australia Ltd. pay dividends?
Cronos Australia Ltd. pays a Notavailable dividend of AU$0.002 which represents an annual dividend yield of 10.53%. See more information on Cronos Australia Ltd. dividends here
What is Cronos Australia Ltd.’s EPS estimate?
Cronos Australia Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cronos Australia Ltd. have?
Cronos Australia Ltd. has 662,741,800 shares outstanding.
What happened to Cronos Australia Ltd.’s price movement after its last earnings report?
Cronos Australia Ltd. reported an EPS of -AU$0.005 in its last earnings report. Following the earnings report the stock price went down -16.129%.
Which hedge fund is a major shareholder of Cronos Australia Ltd.?
Currently, no hedge funds are holding shares in AU:VIT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cronos Australia Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:VIT Sentiment 100%
Sector Average 63%
Sector Average 63%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.76%
12-Months-Change
Fundamentals
Return on Equity
10.53%
Trailing 12-Months
Asset Growth
1.65%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cronos Australia Ltd.
Established in 2018 and based in South Yarra, Australia, Vitura Health Limited focuses on the supply and marketing of medicinal cannabis goods throughout Australia and the Asian market. The company manages a portfolio of key brands, such as CanView, Burleigh Heads Cannabis, CDA Clinics, Cannadoc, and Adaya. This entity was formerly recognized as Cronos Australia Limited before adopting the name Vitura Health Limited in February 2023.
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Vita Life Sciences Limited
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―